PIN31 TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH SKIN AND SOFT TISSUE INFECTIONS IN BELGIUM
Akhras K 1 , Spaepen E 2 , Merchant S 3 , Annemans L 4 1 Johnson and Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 2 IMS Health, Brussels, BRUSSELS, Belgium, 3 Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA, 4 Ghent University, Gent, Belgium OBJECTIVES: Skin and soft tissue infection (SSTI) is a heterogeneous disease caused predominantly by Staphylococcus aureus and Gram-negative pathogens. The choice of anti-infective therapy varies depending on patterns of pathogen resistance, including prevalence of methicillin-resistant Staphylococcus aureus (MRSA). The objective of this study is to understand treatment patterns and outcomes in patients with SSTI in Belgium. METHODS: Data obtained from January-June 2004 Minimum Basic Data Set from 37 hospitals in Belgium, representing approximately 27% of total hospital beds, were used to identify patients hospitalized with SSTI using ICD-9 diagnostic codes and use of at least one intravenous antibiotic. Prescription claims were used to classify AI use into categories based on spectrum of activities, and were further divided into three categories: patients who received a broad spectrum agent and no anti-MRSA coverage (A), patients received a broad spectrum and later switch to (or add) anti-MRSA agent (B), and patients who received anti-MRSA and no broad spectrum agents (C). Anti-MRSA coverage classification was based on use of glycopeptides (vancomycin and teicoplanin). Costs are expressed in 2004 Euros RESULTS: A total of 607 patients were included in this study. The overall proportion of patients treated with anti-MRSA (groups B + C) was 16%. The number of co-diagnoses for groups A, B, and C were 13.5, 20.5, and 15.5, respectively. Mean (median) length of stay (LOS) was 29.4 (19.0), 42.2 (34.0) and 32.9 (24.5) for groups A, B, and C, respectively. Mortality rate was 13.3%, 30.2%, and 18.5% and median total costs were 8,423.00, 19,071.99 and 11,057.61 Euros, for groups A, B, and C, respectively. CONCLUSION: Patients who develop SSTI with MRSA are very costly. Early identification of patients at risk of SSTI involving MRSA and timely administration of appropriate AI therapy has significant implications on reducing costs and improving outcomes.
PIN32 OUTCOMES AND COSTS OF HOSPITAL-ACQUIRED PNEUMONIA ASSOCIATED WITH PSEUDOMONAS OR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN A SAMPLE OF BELGIAN HOSPITALS
Merchant S 1 , Akhras K 1 , Spaepen E 2 , Annemans L 3 1 Johnson and Johnson Pharmaceutical Services, L.L.C, Raritan, NJ, USA, 2 IMS Health, Brussels, Belgium, 3 Ghent University, Gent, Belgium OBJECTIVES: The purpose of this study was to evaluate outcomes and costs of Ventilator-Associated Pneumonia (VAP) and Nosocomial Pneumonia (NP) caused by Pseudomonas or Methicillin-Resistant Staphylococcus Aureus (MRSA). METHODS: Data analyses were performed using the January-June 2004 Minimum Basic Dataset that included data from 37 Belgian hospitals. NP patients were identified using an ICD-9-CM code of bacterial pneumonia (481.xx-486.xx) and at least one IV antibiotic administration during their hospital stay. Patients receiving mechanical ventilation were identified using the ICD-9-CM procedure code 96.7 and its sub-codes. VAP and NP patients were further classified based on the infecting pathogen: Pseudomonas, MRSA, or Other. RESULTS: A total of 287 VAP patients and 757 NP patients and were included in the analyses. VAP patients were sicker and had worse outcomes (hospital length of stay or LOS, mortality, and total hospital costs) than NP patients. VAP/NP patients with Pseudomonas or MRSA were older and sicker compared to VAP/NP in the Other group. LOS (days) for the VAP patients in the Pseudomonas (37) and MRSA (31) groups were higher than in the Other (29) group. For NP, the median LOS for the Pseudomonas (29) and MRSA (31) were higher than in Other (21). Hospital costs for the Pseudomonas group (Euros) were VAP = €31,602, NP = €13,832; for the MRSA group were VAP = €17,767; NP = €17,208; and Other group were VAP = €18,965, NP = €10,687. Mortality rates were higher in the Pseudomonas group (VAP = 54%, NP = 27%) compared to the Other group (VAP = 36%, NP = 16%); the numbers for MRSA were VAP = 27%, NP = 36%. The number of patients in the VAP-MRSA group (n = 11) was too small to make any meaningful conclusions. CONCLUSION: Overall, VAP patients had significantly worse outcomes and higher costs compared to NP patients. Pseudomonas-infected VAP/NP patients and MRSA-infected NP patients had worse outcomes and higher costs compared to VAP/NP patients infected with other pathogens. Abstracts A445
